Evidence map›Paper›PMID 40959321›Full record

ArticleCureus2025

Sensitivity Analysis of a New Cancer Risk Assessment Tool That Evaluates Salivary Polyamines.

Motohiro Kurose, Masahiro Umeda, Sakiko Soutome, Teruyuki Niimi, Hideto Imura, Kayo Hayami, Masako Yoshimatsu, Takashi Ukai, Shuji Nomoto, Nagato Natsume

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Motohiro KuroseDivision of Research and Treatment for Oral and Maxillofacial Congenital Anomalies, School of Dentistry, Aichi Gakuin University, Nagoya, JPN.
Masahiro UmedaDivision of Research and Treatment for Oral and Maxillofacial Congenital Anomalies, School of Dentistry, Aichi Gakuin University, Nagoya, JPN.
Sakiko SoutomeDepartment of Oral Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, JPN.
Teruyuki NiimiDivision of Research and Treatment for Oral and Maxillofacial Congenital Anomalies, School of Dentistry, Aichi Gakuin University, Nagoya, JPN.
Hideto ImuraDivision of Research and Treatment for Oral and Maxillofacial Congenital Anomalies, School of Dentistry, Aichi Gakuin University, Nagoya, JPN.
Kayo HayamiDivision of Research and Treatment for Oral and Maxillofacial Congenital Anomalies, School of Dentistry, Aichi Gakuin University, Nagoya, JPN.
Masako YoshimatsuOral Management Center, Nagasaki University Hospital, Nagasaki, JPN.
Takashi UkaiOral Management Center, Nagasaki University Hospital, Nagasaki, JPN.
Shuji NomotoDepartment of Surgery, Aichi Gakuin University Hospital, Nagoya, JPN.
Nagato NatsumeDivision of Research and Treatment for Oral and Maxillofacial Congenital Anomalies, School of Dentistry, Aichi Gakuin University, Nagoya, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA method to assess cancer risk through salivary-polyamine analysis (SalivaChecker®, SalivaTech Co., Ltd., Tsuruoka, Japan) has been developed. However, studies evaluating the utility of this test in patients with cancer are lacking. Therefore, we evaluated the sensitivity of the SalivaChecker® test in patients with confirmed cancer. MATERIALS AND

methodsThe SalivaChecker® test was performed in 66 patients with confirmed cancer. The risk of six types of cancer (lung, pancreatic, gastric, colorectal, breast (for women only), and oral cancers) was assessed.

resultsThe overall cancer detection rate, which is defined as the rate of detecting the risk for any cancer in the individual, was 68.2%. The detection rates according to the cancer site were as follows: lung cancer (13/14), pancreatic cancer (8/14), gastric cancer (4/6), colorectal cancer (12/17), breast cancer (3/8), and oral cancer (5/7). The overall cancer site detection rate, which was defined as correctly identifying the cancer site, was 28.8%. The detection rates for individual cancers were as follows: lung cancer (4/14), pancreatic cancer (7/14), gastric cancer (3/6), colorectal cancer (1/17), breast cancer (3/8), and oral cancer (1/7).

conclusionThe sensitivity of the SalivaChecker® was 68.2%. Future studies should assess the specificity of this test in patients without cancer to further evaluate its utility.

Indexed as

cancerpancreatic cancerpolyaminepreventive medicinescreeningsensitivity

Identifiers

PMID40959321
PMCPMC12435092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.